SCHEMBL3352486

SCHEMBL3352486

Clc1nc(Cl)nc(NC2CCCC2)n1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 2/20 0.72
RAB9A P51151 1/20 0.57
KDM4E B2RXH2 1/20 0.47
GAA P10253 1/20 0.47
KMT2A Q03164 1/20 0.43
PTGS2 P35354 1/20 0.41
CYP2C9 P11712 1/20 0.40
NPR3 P17342 1/20 0.40
CYP2C19 P33261 1/20 0.40
PDE10A Q9Y233 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
CTSV O60911 1/20 0.39
PLAT P00750 1/20 0.39
CTSL P07711 1/20 0.39
CTSH P09668 1/20 0.39
CTSS P25774 1/20 0.39
CASP14 P31944 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21260552 0.98 PDE4A (0.76) PDE4ARAB9AKDM4EGAAKMT2A
SCHEMBL21260553 0.98 PDE4A (0.76) PDE4ARAB9AKDM4EGAAKMT2A
SCHEMBL39294 0.98 PDE4A (0.76) PDE4ARAB9AKDM4EGAAKMT2A
SCHEMBL5033894 0.98 PDE4A (0.76) PDE4ARAB9AKDM4EGAAKMT2A
SCHEMBL18163295 0.98 PDE4A (0.76) PDE4ARAB9AKDM4EGAAKMT2A
SCHEMBL15131558 0.95 PDE4A (0.67) PDE4ARAB9AKDM4EGAAKMT2A
SCHEMBL18557113 0.93 PDE4A (0.82) PDE4ARAB9AKDM4EGAAKMT2A
SCHEMBL18760598 0.93 PDE4A (0.82) PDE4ARAB9AKDM4EGAAKMT2A
SCHEMBL18557112 0.93 PDE4A (0.82) PDE4ARAB9AKDM4EGAAKMT2A
SCHEMBL20402878 0.93 PDE4A (0.82) PDE4ARAB9AKDM4EGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827920-B2 Nanostructure, a biosensor including the nanostructure, and a screening method POSTECH Research and Business Development Foundation (KR) 2023-11-28 US disclosed
US-11827920-B2 Nanostructure, a biosensor including the nanostructure, and a screening method POSTECH Research and Business Development Foundation (KR) 2023-11-28 US disclosed
WO-2020146779-A1 mTORC1 INHIBITORS FOR ACTIVATING AUTOPHAGY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2020-07-16 WO disclosed
WO-2018175958-A1 THIOREDOXIN MODULATORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2018-09-27 WO disclosed
WO-2010059418-A1 SUBSTITUTED TRIAZINE AND PURINE COMPOUNDS, METHODS OF INHIBITING CRUZAIN AND RHODESAIN AND METHODS OF TREATING CHAGAS DISEASE AND AFRICAN TRYPANOSOMIASIS THE GOVERNMENT OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES (US) 2010-05-27 WO disclosed
WO-2010059418-A1 SUBSTITUTED TRIAZINE AND PURINE COMPOUNDS, METHODS OF INHIBITING CRUZAIN AND RHODESAIN AND METHODS OF TREATING CHAGAS DISEASE AND AFRICAN TRYPANOSOMIASIS THE GOVERNMENT OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES (US) 2010-05-27 WO disclosed
EP-1590341-B1 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION WARNER LAMBERT CO (US) 2009-06-17 EP disclosed
EP-1590341-A1 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION WARNER-LAMBERT COMPANY (US) 2005-11-02 EP disclosed
US-20040236084-A1 E.g., 4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile; potent inhibitors of cyclin-dependent kinases useful in treating cell proliferative disorders PFIZER INC 2004-11-25 US disclosed
WO-2004065378-A1 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION WARNER-LAMBERT COMPANY LLC (US) 2004-08-05 WO disclosed
US-4615727-A Cycloalkyl amino-s-triazines and their use as selective agents against weeds and noxious grasses CHEMISCHE WERKE HULS AKTIENGESELLSCHAFT (DE) 1986-10-07 US disclosed
EP-0096189-A2 Use of possibly substituted thiomethyl-cycloalkylamino-s-triazine as a selective agent against weeds and grasses HÜLS AKTIENGESELLSCHAFT (DE) 1983-12-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040236084-A1 E.g., 4-Cyclopentylamino-2-(5-piperazin-1-yl-pyridin-2-ylamino)-pyrimidine-5-carbonitrile; potent inhibitors of cyclin-dependent kinases useful in treating cell proliferative disorders CDK4, CCNA1, CCNI PDE4A 1463/4885RAB9A 3087/4885KDM4E 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.